TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Affluent Medical SA ( (FR:AFME) ) has issued an update.
Affluent Medical has achieved a significant milestone by completing the pilot phase of its Artus urinary sphincter clinical study. This phase included ten successful minimally invasive implantations, demonstrating a promising safety profile and device activation rate. The results pave the way for a pivotal phase in Q2 2025, aiming to validate the device’s effectiveness on a larger scale and potentially extend its use to women, addressing a major public health issue affecting over 400 million people worldwide.
More about Affluent Medical SA
Affluent Medical is a French medical technologies company founded by Truffle Capital, focusing on innovative implantable devices for treating structural heart diseases and urinary incontinence. The company aims to lead the market with next-generation, minimally invasive, and biomimetic implants designed to restore essential physiological functions, with plans to market its products from 2026.
YTD Price Performance: -1.19%
Average Trading Volume: 2,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €51.12M
For an in-depth examination of AFME stock, go to TipRanks’ Stock Analysis page.